KRAS and melanoma: The pathogenic BRAF variant was found in 14 patients (45.2%, in malignant melanoma patients only), NRAS in 12 patients (38.7%), TP53 in 8 (25.8%), KRAS in 3 (9.7%), ARID2 in 3 (9.7%), and CDKN2 A in 3 (9.7%); other pathogenic variants were less common.